US Full Prescribing Information for EVOTAZ and REYATAZ | Patient Information
INDICATIONS for EVOTAZ® (atazanavir and cobicistat) and REYATAZ® (atazanavir) (200 mg/300 mg capsules)
EVOTAZ is a fixed dose combination of atazanavir and cobicistat, and is indicated for use with other antiretroviral agents for the treatment of HIV-1 infection in adults.
REYATAZ is indicated for use with other antiretroviral agents for the treatment of HIV-1 infection for patients 3 months and older weighing at least 5 kg.
Limitations of Use
- Use of EVOTAZ or REYATAZ/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions
- REYATAZ is not recommended for use in pediatric patients <3 months of age due to the risk of kernicterus